A phase 2, randomized, double-blind, placebo-controlled study to assess the tolerability and pharmacodynamic effects of CRD-740, a PDE9 inhibitor, in participants with chronic heart failure
11 May 2024 (08:00 - 20:00)
Organised by: 
About the speaker
Tufts Medical Center, Inc., Boston (United States of America)
9 More presentations in this session
Doctor E. Meekers (Genk, BE)
Access the full session
The Event
Heart Failure 2024
11 May - 14 May 2024
You may be interested in
Congress Presentation
Congress Session
